Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSI NYSE:MRK NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$4.84-3.1%$2.91$2.01▼$6.33$724.42M2.064.92 million shs8.23 million shsMRKMerck & Co., Inc.$83.67-0.5%$83.76$73.31▼$110.19$208.95B0.3714.86 million shs7.35 million shsRXRXRecursion Pharmaceuticals$6.26-7.9%$5.10$3.79▼$12.36$2.72B0.9128.01 million shs187.46 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci+28.21%+19.62%+90.84%+73.61%+25.63%MRKMerck & Co., Inc.-0.84%-2.64%+3.74%+3.09%-24.60%RXRXRecursion Pharmaceuticals+15.28%+11.49%+42.35%+23.01%+1.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$4.84-3.1%$2.91$2.01▼$6.33$724.42M2.064.92 million shs8.23 million shsMRKMerck & Co., Inc.$83.67-0.5%$83.76$73.31▼$110.19$208.95B0.3714.86 million shs7.35 million shsRXRXRecursion Pharmaceuticals$6.26-7.9%$5.10$3.79▼$12.36$2.72B0.9128.01 million shs187.46 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci+28.21%+19.62%+90.84%+73.61%+25.63%MRKMerck & Co., Inc.-0.84%-2.64%+3.74%+3.09%-24.60%RXRXRecursion Pharmaceuticals+15.28%+11.49%+42.35%+23.01%+1.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 2.71Moderate Buy$7.9863.89% UpsideMRKMerck & Co., Inc. 2.29Hold$105.0023.80% UpsideRXRXRecursion Pharmaceuticals 2.17Hold$7.258.66% UpsideCurrent Analyst Ratings BreakdownLatest ABSI, MRK, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$84.00 ➝ $95.0010/8/2025ABSIAbsciWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MRKMerck & Co., Inc.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025ABSIAbsciJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight9/27/2025ABSIAbsciWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MRKMerck & Co., Inc.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/17/2025MRKMerck & Co., Inc.Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$100.00 ➝ $90.009/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.008/18/2025ABSIAbsciMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.40 ➝ $5.89(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$4.53M160.68N/AN/A$1.56 per share3.12MRKMerck & Co., Inc.$63.62B3.33$9.48 per share8.95$18.33 per share4.63RXRXRecursion Pharmaceuticals$58.84M49.23N/AN/A$2.61 per share2.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$103.11M-$0.94N/AN/AN/A-2,737.94%-60.21%-50.85%11/11/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.4913.078.570.9325.79%41.05%16.55%10/30/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest ABSI, MRK, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025ABSIAbsci-$0.19N/AN/AN/A$1.58 millionN/A11/5/2025Q3 2025RXRXRecursion Pharmaceuticals-$0.35N/AN/AN/A$19.36 millionN/A10/30/2025Q3 2025MRKMerck & Co., Inc.$2.37N/AN/AN/A$17.00 billionN/A8/12/2025Q2 2025ABSIAbsci-$0.19-$0.24-$0.05-$0.24$1.39 million$0.59 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.243.82%N/A49.92%14 YearsRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest ABSI, MRK, and RXRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025MRKMerck & Co., Inc.quarterly$0.814%9/15/20259/15/202510/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsciN/A4.394.39MRKMerck & Co., Inc.0.691.421.17RXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%MRKMerck & Co., Inc.76.07%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipABSIAbsci10.49%MRKMerck & Co., Inc.0.13%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210149.52 million133.84 millionOptionableMRKMerck & Co., Inc.75,0002.50 billion2.49 billionOptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableABSI, MRK, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - Time to Buy?1 hour ago | marketbeat.comTop Biotech Stocks To Keep An Eye On - October 16th3 hours ago | marketbeat.comRecursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event5 hours ago | insidermonkey.comIs Recursion Pharmaceuticals a Millionaire Maker?October 16 at 10:08 AM | fool.comRecursion Pharmaceuticals (RXRX) Stock Soars as AI Drug Discovery Hype ReturnsOctober 16 at 9:53 AM | blockonomi.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 12.3% - Time to Buy?October 15 at 1:16 PM | marketbeat.comBiotech Stocks To Consider - October 15thOctober 15 at 1:03 PM | marketbeat.comRecursion Pharmaceuticals call volume above normal and directionally bullishOctober 14 at 6:38 PM | msn.comPromising Biotech Stocks To Follow Today - October 14thOctober 14 at 1:02 PM | marketbeat.com2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (RXRX)...October 13 at 12:12 PM | marketbeat.com4 Healthcare Stocks to Buy NowOctober 12, 2025 | fool.comRecursion Pharmaceuticals (RXRX): Assessing Valuation with AI Strategy in Focus Ahead of Key CEO PresentationOctober 12, 2025 | finance.yahoo.comTraders Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)October 10, 2025 | americanbankingnews.comRecursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall ProgressOctober 9, 2025 | seekingalpha.comRecursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI ConferenceOctober 9, 2025 | insidermonkey.comWeiss Ratings Reiterates "Sell (D-)" Rating for Recursion Pharmaceuticals (NASDAQ:RXRX)October 9, 2025 | marketbeat.comInvestors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)October 8, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.8% - Here's What HappenedOctober 8, 2025 | marketbeat.comBiotech Stocks To Follow Today - October 8thOctober 8, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory October 8, 2025 | insidermonkey.comRecursion Pharmaceuticals, Inc. (RXRX): A Bull Case TheoryOctober 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 20252 Reasons Absci Could Be the Future of AI Biotech, and 1 RiskBy Nathan Reiff | October 13, 20255 Healthcare Plays Powering the Sector’s Big ComebackBy Ryan Hasson | October 9, 2025ABSI, MRK, and RXRX Company DescriptionsAbsci NASDAQ:ABSI$4.84 -0.16 (-3.12%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Merck & Co., Inc. NYSE:MRK$83.67 -0.44 (-0.52%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Recursion Pharmaceuticals NASDAQ:RXRX$6.26 -0.54 (-7.88%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
